What Is Fenbendazole? Veterinary Uses, Human Safety and Cancer Research
What Is Fenbendazole?
Fenbendazole is an antiparasitic medicine used in veterinary medicine to treat certain worm infections and other susceptible parasites. It belongs to the benzimidazole family of anthelmintics, a group of medicines commonly known as dewormers. Its established role is in animal parasite treatment; it is not an approved human cancer medicine.
For pet owners, fenbendazole may be prescribed or recommended when a dog or cat has a particular parasitic infection. Depending on the product and its authorized indications, treatment may target certain intestinal worms, specific lungworms, or Giardia in dogs. These uses are not interchangeable: a medicine that treats one parasite may not treat another, and the appropriate course depends on the diagnosis.
Fenbendazole is the name of the active ingredient, rather than one specific product. Veterinary formulations include granules, oral suspensions and pastes. Product strengths, target species and approved uses can differ, so instructions for one formulation should not automatically be applied to another. The animal’s weight and the infection being treated also matter when selecting a treatment plan.
Interest in fenbendazole has expanded beyond veterinary medicine because of online discussions about cancer. However, laboratory research and personal testimonials do not establish that a medicine safely treats cancer in people. Fenbendazole is not approved for any human use in the United States, and reliable clinical evidence has not established it as an effective human cancer treatment. Its veterinary use should therefore be understood separately from claims circulating on social media.
How Does Fenbendazole Work?
Fenbendazole works by interfering with structures inside susceptible parasites called microtubules. These structures are built from a protein called tubulin and support essential cellular functions.
The medicine binds to beta-tubulin, disrupting the formation of microtubules. This interferes with the parasite’s energy metabolism and its ability to maintain normal cellular activity, contributing to its death. This mechanism explains fenbendazole’s use as an antiparasitic medicine.
Its effects depend on the parasite involved and the treatment used. Some veterinary indications include activity against both immature and adult worms, but this does not mean fenbendazole eliminates every parasite or every stage of every infection. The correct product and treatment duration remain essential.
Microtubules also play a role in cell division, which helps explain scientific interest in investigating medicines that affect them. Nevertheless, a biological mechanism is only a starting point for research. Showing an effect on cancer cells in a laboratory does not demonstrate that a drug will reach a tumor at a safe, effective concentration in a person—or improve survival or quality of life.
Fenbendazole’s established antiparasitic action does not prove an anticancer benefit in humans. That question requires carefully designed clinical studies evaluating effectiveness, dosing and harm. Veterinary treatment instructions cannot answer those questions or serve as a human treatment protocol.
What Parasites Does Fenbendazole Treat?
Fenbendazole treats several types of parasitic worms, but its coverage depends on the parasite species, the animal being treated and the product used. Describing it as a broad-spectrum dewormer does not mean it treats every parasitic infection.
For example, approved canine products in the United States target the following intestinal worms:
Parasite group | Examples covered by approved canine products |
Roundworms | Toxocara canis and Toxascaris leonina |
Hookworms | Ancylostoma caninum and Uncinaria stenocephala |
Whipworms | Trichuris vulpis |
Certain tapeworms | Taenia pisiformis |
The species distinction matters, particularly with tapeworms. A product labeled for Taenia pisiformis should not be assumed to treat every tapeworm infection. If worms or segments remain visible after treatment, the next step is veterinary reassessment rather than repeatedly giving the same medicine.
Some veterinary products also have indications for specific respiratory parasites. For example, certain UK-authorized formulations include the canine lungworm Oslerus osleri and the feline lungworm Aelurostrongylus abstrusus. These indications do not establish effectiveness against every parasite commonly called a “lungworm.”
Fenbendazole may also be used for Giardia in dogs. Giardia is a microscopic protozoan parasite, rather than a worm, and product approval for this use varies by country. Treatment decisions should consider symptoms, test findings and the animal’s circumstances; an otherwise healthy dog with a positive Giardia test does not automatically need medication.
Fenbendazole is also not a substitute for heartworm prevention. A dog receiving an intestinal dewormer may still need a separate preventive program suited to its location and exposure risks.
Fenbendazole for Dogs: Uses and Treatment Considerations
Fenbendazole has an established role in treating susceptible intestinal worms in dogs. A veterinarian may also select it for certain other parasitic infections, including circumstances where the intended use falls outside the local product label. Such use requires a treatment decision specific to the patient and infection.
Before starting treatment, the practical questions include:
Which parasite is being targeted? Different infections may require different medicines or treatment durations.
What does the dog weigh? An accurate weight helps avoid dosing errors.
Which formulation is being used? The concentration and instructions must match the actual product.
Does the dog meet the product’s age and health requirements? For example, some US canine granules are labeled for dogs aged six weeks and older.
How will the full course be administered? For granules mixed into food, the dog must consume the entire medicated portion.
For Giardia, medication may be only one part of management. Prompt stool removal, cleaning fecally contaminated materials and bathing when advised can help limit reinfection. Persistent symptoms do not automatically mean that a higher dose or longer course is needed. Reinfection, incomplete administration and other explanations for treatment failure require reassessment. Some Giardia tests can remain positive after treatment, so results must be interpreted alongside the dog’s clinical condition.
Do not extend treatment on your own because fenbendazole is commonly used as a dewormer. Reports of bone marrow suppression and reductions in multiple blood cell types have been associated with courses longer than the labeled duration in dogs. These reports do not establish how frequently this occurs, but they show why prolonged treatment requires veterinary judgment. Approved use at the labeled dose and duration remains supported as safe and effective.
Fenbendazole for Cats: Uses and Veterinary Guidance
Fenbendazole can be used in cats to treat certain parasitic infections, but the appropriate product and treatment plan must be selected for the cat. A canine treatment schedule should not automatically be transferred to a feline patient.
In some countries, veterinary fenbendazole products are specifically authorized for cats. For example, a UK-authorized granule formulation includes treatment of certain gastrointestinal worms and the feline lungworm Aelurostrongylus abstrusus. This illustrates why statements about approval must identify the country, product and intended use: a medicine’s status is not necessarily the same everywhere.
Veterinarians may also use fenbendazole for Giardia in cats, although evidence on treatment effectiveness in this species is limited. In the United States, no medicine is approved specifically for feline giardiasis, so treatment involves extra-label prescribing. This means using a medicine outside its approved labeling under veterinary direction.
A positive Giardia result should be interpreted alongside the cat’s symptoms and circumstances. A cat with persistent diarrhea may need treatment, while an otherwise healthy cat without symptoms may not. Repeated treatment courses are not automatically appropriate simply because a test remains positive. Some antigen and PCR tests can remain positive after treatment and should not, by themselves, be used to declare treatment failure.
For cats being treated for Giardia, environmental management also matters. Removing feces promptly, cleaning contaminated surfaces and allowing cleaned areas to dry can help reduce exposure. Medication alone cannot prevent a cat from encountering the parasite again in a contaminated environment.
Owners should leave treatment changes to the prescribing veterinarian, particularly when symptoms persist. Continuing the same medicine without reassessment may overlook reinfection, incomplete dosing or another explanation for the cat’s illness.
Fenbendazole Dosage in Animals: Why Species, Product and Diagnosis Matter
There is no single fenbendazole dosing schedule that applies to every animal and every parasitic infection. The amount given, dosing interval and treatment duration must be considered together.
As one specific example, approved US canine fenbendazole products use a labeled regimen of 50 mg/kg by mouth once daily for three consecutive days for their listed intestinal worm indications. This is a product-specific veterinary regimen—not a universal schedule for cats, other parasites or human use.
Several factors determine how a veterinarian selects and explains treatment:
Factor | Why it matters |
Animal species | A product’s approved uses and supporting safety information may differ between species. |
Weight-based dosing requires a current, reasonably accurate measurement. | |
Parasite being treated | Different infections can require different treatment schedules. |
Product concentration | The amount of active medicine per gram or milliliter determines how much product is administered. |
Treatment duration | A longer course is a separate clinical decision, not simply an extension of routine deworming. |
Product concentration is particularly important. Milligrams of fenbendazole are not the same as milligrams of the finished powder, and milliliters measure liquid volume rather than drug dose. Two formulations containing the same active ingredient may require different quantities to deliver the same amount of medicine. Owners should therefore follow instructions for the exact product supplied.
Treatment duration also affects safety. Bone marrow suppression and reductions in blood cell counts have been reported in dogs receiving fenbendazole for longer than the labeled course. Such reports do not mean every extended course is inappropriate, but they reinforce the need for veterinary assessment before prolonging treatment.
Before giving the first dose, owners should have clear instructions stating the product name and strength, amount per dose, frequency and number of treatment days. If the packaging differs from what was prescribed, confirm the instructions before administering it.
How Is Fenbendazole Given to Dogs and Cats?
Fenbendazole is given by mouth, using the formulation and schedule selected for the animal. Before administration, check the product name, concentration and prescribed amount. Instructions for a different formulation—even one containing fenbendazole—may not apply.
Granules intended for mixing with food should be blended into a small portion of the pet’s usual meal so that the entire medicated portion is consumed. Mixing the medicine into a large bowl that the animal may leave unfinished makes it difficult to know how much was swallowed. In households with several pets, feed the treated animal separately to prevent another animal from eating the medication.
Liquid formulations require careful measurement. Use the measuring device supplied or recommended for the product, and follow its preparation instructions. Giving fenbendazole with food can help reduce gastrointestinal upset. Complete the prescribed course unless the veterinarian advises a change.
If your pet refuses the medicated food, spits out medicine or vomits after administration, contact the veterinary clinic before replacing the dose. Explain which product was used, when it was given and how much you believe the animal swallowed. Do not automatically give another full dose when the amount already received is uncertain.
If a dose is missed, do not double the next dose. Ask the prescribing veterinarian how to continue, particularly when treatment requires consecutive daily doses. Keeping a simple record of each administration can help prevent missed or duplicate doses.
Wash your hands after handling the medicine. When using granules, avoid inhaling the dust and minimize contact with the skin and eyes. Follow the storage instructions on the actual package, keeping the product out of children’s reach.
What Are the Side Effects of Fenbendazole in Animals?
Fenbendazole is generally well tolerated when used for the appropriate indication at the recommended dose and duration. However, adverse effects can occur, and being a commonly used dewormer does not make it risk-free.
Reported gastrointestinal effects include vomiting and diarrhea. Their reported frequency varies between products and the information used to assess them, so a percentage from one formulation should not be applied to every fenbendazole product. Gastrointestinal illness during treatment also does not automatically prove that the medicine caused it; the underlying infection or another condition may contribute. Report new or worsening symptoms to the veterinarian.
Drooling can also occur. Rare allergic reactions may involve facial swelling, hives or marked itching. A suspected serious reaction requires immediate veterinary attention; do not give another dose while waiting for advice.
A more serious concern is bone marrow suppression associated with prolonged treatment in reported canine cases. Bone marrow produces blood cells, and suppression can result in pancytopenia—a reduction in red blood cells, white blood cells and platelets.
Reported cases involved treatment lasting longer than the three-day course on the relevant US canine labels. These reports identify a safety concern but cannot establish the overall frequency of the complication or mean that every veterinarian-directed extended course will cause harm.
If an adverse reaction or dosing error is suspected, contact the veterinary clinic promptly and keep the packaging available. The product strength, amount administered, treatment dates and timing of symptoms help the veterinarian assess what happened and decide whether examination or testing is needed.
When Should Fenbendazole Be Avoided or Used With Caution?
Fenbendazole should be used according to the specific product instructions and the animal’s clinical needs. Age, pregnancy, existing illness and the proposed treatment duration can all affect whether a particular formulation or schedule is appropriate.
Very young animals need product-specific assessment. Some US canine formulations are labeled for puppies aged six weeks and older, but that age limit should not be treated as a universal rule covering every formulation and species. An unwell puppy or kitten should be assessed rather than automatically given an over-the-counter dewormer.
Pregnancy also requires attention to the actual label. Some fenbendazole products permit use during pregnancy, including particular canine parasite-control protocols. However, this does not establish that every regimen is suitable throughout gestation. A UK-authorized product specifically calls for a veterinary benefit–risk assessment during the first two-thirds of pregnancy. Do not assume that “safe in pregnant dogs” means unrestricted use in every pregnant animal.
Tell the veterinarian about existing medical conditions, previous medication reactions and all medicines or supplements the animal receives. Liver or kidney disease may prolong the medicine’s effects. A history of a suspected reaction should be discussed before another course is started.
Longer treatment courses deserve particular care because bone marrow suppression has been reported in dogs receiving fenbendazole beyond the labeled duration. Whether an extended course is justified depends on the infection and the individual patient; owners should not lengthen treatment independently.
Repeated deworming without reassessment is also inappropriate when treatment appears unsuccessful. Underdosing and frequent, prolonged use of medicines from the same anthelmintic class can contribute to resistance. The next step should be to review the diagnosis, administration and reinfection risk with the veterinarian.
Is Fenbendazole Approved for Human Use?
Fenbendazole is not approved for human use in the United States, including for treating cancer or parasitic infections. Its established medical role is as a veterinary antiparasitic. Approval to treat animals does not establish a safe or effective treatment for people.
Veterinary dosing instructions cannot be converted into a human treatment plan simply by adjusting for body weight. Human use requires evidence about absorption, dosing, adverse effects and interactions, as well as whether treatment improves meaningful health outcomes. Those questions have not been adequately answered for fenbendazole as a human cancer treatment.
Online availability, personal testimonials and references to laboratory research do not change its approval status. Likewise, describing a regimen as a “protocol” does not mean it has undergone clinical validation. There is no established, approved fenbendazole regimen for treating human cancer.
People considering fenbendazole because of a cancer diagnosis should discuss the claims with their oncology team before taking it. That conversation can address the available evidence, potential harms and suitable clinical trials. Fenbendazole should not replace or delay established cancer care.
Fenbendazole and Cancer: What Does the Research Actually Show?
Fenbendazole has attracted interest in cancer research, but it has not been established as a safe and effective cancer treatment in humans. The distinction between experimental findings and clinical benefit is essential when interpreting claims about this medicine.
Laboratory research has investigated whether fenbendazole can disrupt processes that cancer cells depend on. A published experimental study reported effects involving microtubules and other cellular pathways associated with cancer cell death. Such findings can help researchers identify questions worth investigating, but they do not establish a treatment that patients can safely use.
The evidence needs to be understood at several different levels:
Type of evidence | What it can tell us | What it cannot establish on its own |
Experiments in cultured cancer cells | Whether a substance affects cells under specific laboratory conditions | Whether it safely treats cancer in a person |
Animal experiments | How a treatment behaves in a particular experimental model | Whether the same benefit will occur in human patients |
Individual patient reports | What happened during one person’s treatment | Whether fenbendazole caused the outcome |
Carefully designed clinical trials | Safety, dosing and treatment outcomes in defined patient groups | A benefit for every cancer or every patient |
Laboratory and animal findings have prompted interest, but reliable clinical evidence has not established that fenbendazole improves survival or provides an effective human cancer treatment. Important questions about dosing, safety and interactions remain unresolved.
Clinical testing addresses these questions in stages. Early trials evaluate safety and dosing, while later studies assess effectiveness and compare treatments. A plausible mechanism or an encouraging experimental result cannot replace that process.
Fenbendazole should not be used to treat cancer—or added to established cancer treatment—outside the safeguards of a properly designed clinical trial. Research interest is a reason to investigate a medicine carefully, not a basis for recommending self-treatment.
Why Laboratory Findings and Personal Stories Do Not Prove a Cancer Treatment Works
A claim that a substance “kills cancer cells” can sound decisive. However, a laboratory experiment answers a narrower question: what happens to selected cells under the conditions of that experiment? It does not automatically show whether a person can safely receive enough of the substance to produce a useful treatment effect.
Researchers must also establish whether a treatment’s benefits outweigh its harms. Effects observed in cells or experimental animals may not translate into improved outcomes for patients. This is why laboratory research is an early step in drug development rather than proof of a cancer cure.
Personal recovery stories present a different problem: improvement after taking a medicine does not prove improvement because of that medicine. Someone sharing a fenbendazole success story may also have received surgery, chemotherapy, immunotherapy or another established treatment. Without an appropriate comparison, the contribution of fenbendazole cannot be separated from those treatments.
For example, a widely circulated account attributed recovery from lung cancer to fenbendazole even though the person was also receiving an immunotherapy treatment through a clinical study. The story cannot establish which treatment caused the response. Recognizing this limitation does not question the person’s experience; it questions the conclusion drawn from it.
Controlled clinical trials help address this uncertainty by comparing groups and measuring outcomes systematically. Random assignment can reduce differences between groups that might otherwise make a treatment appear more effective than it is. Researchers also record adverse effects rather than focusing only on favorable outcomes.
When evaluating a claim, ask: Was this tested in people? What other treatments did they receive? Was there a comparison group? Were benefits and harms measured consistently? These questions help distinguish an interesting observation from evidence strong enough to guide cancer care.
Fenbendazole and Ivermectin: What Is Known About the Combination?
Fenbendazole and ivermectin have not been established as a safe and effective combination for treating human cancer. Online discussions sometimes present them as complementary medicines, but combining two drugs with experimental anticancer findings does not prove that the combination benefits patients.
Although both medicines have antiparasitic uses, they are different drugs. Ivermectin has approved human formulations for certain parasitic infections, whereas fenbendazole is a veterinary medicine without approval for human use in the United States. Approval of ivermectin for a parasitic disease does not establish its effectiveness against cancer or validate its use alongside fenbendazole.
Evaluating a combination requires evidence about the combination itself. Researchers need to determine whether the drugs provide additional benefit together, which doses are tolerable and whether adverse effects or interactions become more likely. Findings about either medicine individually cannot answer all of those questions.
A meaningful clinical study would need to assess issues such as:
Whether adding the combination improves outcomes compared with appropriate cancer care.
Whether any benefit applies to a particular cancer type or patient group.
How the medicines interact with the patient’s other treatments.
Whether potential benefits outweigh side effects and treatment complications.
Controlled trials help distinguish the effects of an investigational treatment from differences between patients or the effects of other therapies they receive.
Neither fenbendazole nor ivermectin should be used as a cancer treatment, including as an addition to established therapy, outside a properly designed clinical trial. Describing the combination as an “add-on” does not remove the need to demonstrate safety and benefit.
Patients who encounter these claims should discuss them openly with their oncology team. Sharing the exact products and proposed regimen allows the team to address the evidence and potential risks without relying on incomplete descriptions from social media.
What Are the Risks of Taking Veterinary Fenbendazole as a Human?
A veterinary product’s safety for its intended animal use does not establish its safety for people. Fenbendazole lacks an established human treatment regimen, and its risks cannot be reliably assessed by copying animal instructions or following an online dosing schedule.
One documented concern is liver injury. A published case report described a patient with lung cancer who developed severe liver dysfunction after taking fenbendazole based on social media claims. Liver function improved after the medicine was stopped, and the authors assessed fenbendazole as a probable cause. The patient did not experience tumor shrinkage during that period. This report identifies a potential harm; it does not establish how frequently liver injury occurs among people taking the drug.
Other concerns include uncertainty about interactions with cancer medicines and the difficulty of identifying the cause of new symptoms or abnormal blood tests. If the care team does not know that someone is taking fenbendazole, it may be harder to distinguish a reaction to self-treatment from a complication of the cancer or prescribed therapy.
The liver-injury case illustrates this problem: clinicians initially considered the patient’s immunotherapy as a possible cause, and cancer treatment was temporarily interrupted. Learning about the fenbendazole use helped clarify the assessment.
There is also a risk of delaying or replacing effective care because an unproven regimen appears promising. Testimonials cannot establish that this trade-off is safe. Continuing prescribed treatment while secretly adding fenbendazole also leaves unresolved safety concerns.
Anyone considering or already using veterinary fenbendazole should tell their treating physician. The product packaging, amount taken, dates of use and any other medicines or supplements are important information for that discussion.
Is There an Established Fenbendazole Dose for Human Cancer Treatment?
There is no established, clinically validated fenbendazole dose for treating cancer in humans. The drug is not approved for human use in the United States, and online schedules do not provide the evidence needed to determine a safe and effective cancer treatment regimen.
An appropriate dose must do more than produce a laboratory effect. Researchers need to establish how the medicine behaves in people, what adverse effects occur and whether treatment benefits patients. These questions remain unresolved for fenbendazole as a human cancer treatment.
Clinical trials investigate dosing systematically. Early studies assess tolerability and adverse effects, while subsequent studies evaluate treatment activity and compare outcomes with existing care. A dose that someone tolerated is not necessarily effective, and a dose associated with an apparent improvement is not automatically safe.
Veterinary instructions cannot fill this evidence gap. Adjusting an animal dose to a person’s body weight does not establish human safety. Similarly, taking breaks between doses or combining fenbendazole with other medicines does not validate an internet “protocol.”
The absence of a validated regimen also means that there is no evidence-based fenbendazole dosing table to recommend for different human cancers. Someone considering the medicine should discuss the research with their oncology team, including whether an appropriate clinical trial is available, rather than selecting a schedule from testimonials.
What Should You Do If You Have Taken Fenbendazole for Cancer?
If you have been taking fenbendazole on your own for cancer, stop self-administering it and contact your treating physician promptly. Tell your oncology team even if you feel well. The purpose is to assess possible harm and protect your ongoing care, not to judge your decision.
Bring the packaging or clear photographs of the label, and provide:
The product name, formulation and concentration.
The amount taken each time and how often you took it.
When you started and when you took the last dose.
Any symptoms or changes in recent blood tests.
All other medicines and supplements used, including ivermectin.
Unexpected liver injury has been reported after self-administration of fenbendazole. In one published case, discovering the patient’s use helped clinicians assess abnormal liver tests that had initially been attributed to cancer immunotherapy. Your clinician may consider blood tests, including liver tests, based on the exposure and your medical circumstances.
Do not independently stop prescribed cancer treatment. Decisions about chemotherapy, immunotherapy or other prescribed medicines should be made with the treating team. Adding an unproven medicine without their knowledge can complicate the assessment of side effects and treatment decisions.
Frequently Asked Questions About Fenbendazole
What is fenbendazole used for?
Fenbendazole is a veterinary antiparasitic used to treat certain worm infections. Depending on the animal, product and local approval, its uses may also include specific lungworms and Giardia in dogs. It does not treat every parasite, so the diagnosis determines whether it is appropriate.
Can cats take fenbendazole?
Yes, veterinarians may use fenbendazole in cats for particular parasitic infections. Some countries have products specifically authorized for cats; other uses involve extra-label prescribing. The formulation and treatment instructions must be appropriate for the cat and the infection.
Does fenbendazole treat Giardia?
Fenbendazole is an option for treating Giardia in dogs and may also be prescribed for cats, although feline treatment evidence is limited. Approval varies by country and species. Treatment decisions should consider symptoms and exposure risks, and environmental hygiene helps reduce reinfection.
Does fenbendazole treat all tapeworms?
No. Certain canine products cover Taenia pisiformis, but that does not establish effectiveness against every tapeworm species. Persistent worms or segments warrant veterinary reassessment rather than automatically repeating treatment.
Can fenbendazole replace a dog’s heartworm preventive?
No. Fenbendazole canine dewormers are not a substitute for heartworm prevention. A veterinarian can recommend an appropriate preventive program alongside treatment for intestinal parasites.
Is fenbendazole safe for long-term use in dogs?
Safety information for a labeled short course should not be extended to indefinite treatment. Bone marrow suppression has been reported in dogs treated for longer than the labeled duration. Extended courses require a veterinary assessment of the expected benefit and potential harm.
Is fenbendazole approved for humans?
No. Fenbendazole is not approved for any human use in the United States. Its veterinary approval does not establish human safety, effectiveness or dosing.
Does fenbendazole cure cancer?
There is no reliable clinical evidence establishing fenbendazole as a cure for human cancer. Experimental findings can justify further research, but personal recovery stories cannot separate its effects from other treatments a person received.
Is fenbendazole the same as ivermectin?
No. They are different antiparasitic medicines. Ivermectin has approved human uses for certain conditions, while fenbendazole does not have human approval in the United States. Neither that distinction nor their antiparasitic activity establishes an effective cancer treatment.
Is combining fenbendazole with ivermectin an effective cancer treatment?
The combination has not been established as a safe and effective human cancer treatment. It should not be used for cancer, including as an addition to established therapy, outside a properly designed clinical trial.
Can fenbendazole cause liver damage in people?
Liver injury has been reported after people self-administered fenbendazole. Published case reports identify a potential risk but do not establish how often it occurs. Anyone who has taken the medicine should disclose this to their treating physician.
References
Source | Full URL |
American Cancer Society / American Society of Clinical Oncology — What to Know About Fenbendazole | |
U.S. Food and Drug Administration — Adverse Events Associated With Extra-Label Use of Fenbendazole in Dogs | |
UK Veterinary Medicines Directorate — Panacur Granules: Product Labeling and Package Leaflet | |
UK Veterinary Medicines Directorate — Fenbendazole Public Assessment Report: Pigfen | |
Merck Animal Health — Safe-Guard Canine Dewormer | |
Companion Animal Parasite Council — Giardia Guidelines | |
VCA Animal Hospitals — Fenbendazole | |
National Cancer Institute — How Do Clinical Trials Work? | |
Scientific Reports — Experimental Study of Fenbendazole and Cancer Cell Pathways | |
Case Reports in Oncology — Drug-Induced Liver Injury Following Self-Administration of Fenbendazole | |
American Society of Clinical Oncology — Clinical Notice Regarding Ivermectin and Fenbendazole for Cancer Treatment | |
U.S. Food and Drug Administration — Ivermectin: Approved Uses and Safety Information | |
National Capital Poison Center — First Aid for Poisonings | |
Mayo Clinic — Poisoning: First Aid | |
Mersin Vetlife Veterinary Calinic |
Comments